Immunological Characteristics between αβ T_DC and γδ T_DC Cells in the Spleen of Breast Cancer-Induced Mice

Abstract

Objective To evaluate the antitumoral role of γδ T_DC cells and αβ T_DC cells in an experimental model of breast cancer.

Methods Thirty female Balb/c mice were divided into 2 groups: control group (n = 15) and induced-4T1 group (n = 15), in which the mice received 2 × 10⁵ 4T1 mammary tumor cell line. Following the 28-day experimental period, immune cells were collected from the spleen and analyzed by flow cytometry for comparison of αβ T_DC (TCRαβ⁺ CD11c⁺MHCII⁺) and γδ T_DC (TCRγδ⁺CD11c⁺MHCII⁺) cells regarding surface markers (CD4⁺ and C8⁺) and cytokines (IFN-γ, TNF-α, IL-12 and IL-17).

Results A total of 26.53% of γδ T_DC - control group (p < 0.0001) - the proportion of αβ T_DC was lower in splenic cells than γδ T_DC; however, these 2 cell types were reduced in tumor conditions (p < 0.0001), and the proportion of IFN-γ, TNF-α, IL-12 and IL-17 cytokines produced by γδ T_DC was higher than those produced by αβ T_DC, but it decreased under conditions of tumor-related immune system response (p < 0.0001).

Conclusion Healthy mice engrafted with malignant cells 4T1 breast tumor presented T_DC with γδ TCR repertoire. These cells express cytotoxic molecules of lymphocytes T, producing anti-tumor proinflammatory cytokines.

Resumo

Objetivo Esclarecer o possível papel antitumoral das células T_DC γδ e T_DC αβ em um modelo experimental de câncer de mama.

Métodos Trinta baços de camundongos Balb/c analisados por citometria de fluxo, separados entre grupo controle (n = 15) e o grupo tumoral induzido por 4T1 (n = 15).

Resultados Presença de 26,53% de T_DC γδ nos camundongos do grupo controle (p < 0,0001), proporção de T_DC αβ menor em células esplênicas do que T_DC γδ; no entanto, estes dois tipos de células são reduzidos em condições tumorais (p < 0,0001), e a proporção de citocinas IFN-γ, TNF-α, IL-12 e IL-17 produzidas pelas célula T_DC γδ foi maior do que as produzidas pelas células T_DC αβ, mas foram diminuídas sob condições de resposta ao sistema imunológico relacionada ao tumor (p < 0,0001).

Conclusão Camundongos saudáveis induzidos ao tumor de mama 4T1 apresentaram T_DC com repertório TCR γδ. Estas células expressam moléculas citotóxicas de linfócitos T, produzindo citocinas proinflamatórias anti-tumor.

Keywords

immunology - breast neoplasms - immunotherapy - T-lymphocytes - receptors

Palavras-chave

imunologia - neoplasias mamárias - imunoterapia - linfócitos T - receptores

• References

• 1 Kuka M, Munitic I, Ashwell JD. Identification and characterization of polyclonal αβ-T cells with dendritic cell properties. Nat Commun 2012; 3: 1223
• 2 Gaulard P, Bourquelot P, Kanavaros P, Haioun C, Le Couedic JP, Divine M. et al. Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. Am J Pathol 1990; 137 (03) 617-628
• 3 Legut M, Cole DK, Sewell AK. The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy. Cell Mol Immunol 2015; 12 (06) 656-668
• 4 Donia M, Ellebaek E, Andersen MH, Straten PT, Svane IM. Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes. OncoImmunology 2012; 1 (08) 1297-1304
• 5 Wang J, Lin C, Li H, Li R, Wu Y, Liu H. et al. Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. OncoImmunology 2017; 6 (11) e1353858
• 6 Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang K-Y, Abhyankar S. et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 2007; 39 (12) 751-757
• 7 Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P. et al. Contribution of IL-17-producing γ δ T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208 (03) 491-503
• 8 Lafont V, Sanchez F, Laprevotte E, Michaud H-A, Gros L, Eliaou J-F. et al. Plasticity of γδ T cells: impact on the anti-tumor response. Front Immunol 2014; 5: 622
• 9 Davey MS, Willcox CR, Hunter S, Kasatskaya SA, Remmerswaal EBM, Salim M. et al. The human Vδ2⁺ T-cell compartment comprises distinct innate-like Vγ9⁺ and adaptive Vγ9⁻ subsets. Nat Commun 2018; 9 (01) 1760
• 10 Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J. et al. The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med 2003; 198 (05) 747-755
• 11 Gaafar A, Aljurf MD, Al-Sulaiman A, Iqniebi A, Manogaran PS, Mohamed GEH. et al. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Exp Hematol 2009; 37 (07) 838-848
• 12 Niu C, Jin H, Li M, Xu J, Xu D, Hu J. et al. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells. BMC Immunol 2015; 16: 61
• 13 Chapman NM, Chi H. Hallmarks of T-cell exit from quiescence. Cancer Immunol Res 2018; 6 (05) 502-508
• 14 Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002; 23 (01) 14-18
• 15 Street SEA, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM. et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med 2004; 199 (06) 879-884
• 16 Liu Z, Eltoum IEA, Guo B, Beck BH, Cloud GA, Lopez RD. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol 2008; 180 (09) 6044-6053
• 17 Lança T, Costa MF, Gonçalves-Sousa N, Rei M, Grosso AR, Penido C. et al. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. J Immunol 2013; 190 (12) 6673-6680
• 18 Born WK, Reardon CL, O'Brien RL. The function of gammadelta T cells in innate immunity. Curr Opin Immunol 2006; 18 (01) 31-38
• 19 Yang Y, Xu C, Wu D, Wang Z, Wu P, Li L. et al. γδ T cells: crosstalk between microbiota, chronic inflammation, and colorectal cancer. Front Immunol 2018; 9: 1483
• 20 Zhao Y, Niu C, Cui J. Gamma-delta (γδ) T cells: friend or foe in cancer development?. J Transl Med 2018; 16 (01) 3
• 21 Wu P, Wu D, Ni C, Ye J, Chen W, Hu G. et al. γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 2014; 40 (05) 785-800
• 22 Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng WO, Kim D. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21 (08) 938-945
• 23 Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH. et al. γ δ T cells provide an early source of interferon γ in tumor immunity. J Exp Med 2003; 198 (03) 433-442
• 24 He W, Hao J, Dong S, Gao Y, Tao J, Chi H. et al. Naturally activated V γ 4 γ δ T cells play a protective role in tumor immunity through expression of eomesodermin. J Immunol 2010; 185 (01) 126-133
• 25 Sebestyen Z, Prinz I, Déchanet-Merville J, Silva-Santos B, Kuball J. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov 2020; 19 (03) 169-184
• 26 Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglina S, Cicero G. et al. Targeting human γδ T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007; 67 (15) 7450-7457
• 27 Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M. et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells. AIDS 2009; 23 (05) 555-565